Skip to main content
. 2021 Apr 14;148(2):475–485. doi: 10.1007/s00432-021-03627-1

Table 3.

Univariate and multivariate analyses of factors associated with overall survival

Parameter Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
High IL-6 4.1 (1.9–8.9)  < 0.001 2.99 (1.22–7.3) 0.017
High IL-8 2.4 (1.2–4.7) 0.009 2.19 (1.02–4.7) 0.044
Sex (male vs. female) 0.79 (0.28–2.3) 0.667
Age (≥ 65 vs. < 65 years) 1.1 (0.55–2.1) 0.85
ECOG PS (1 vs. 0) 0.63 (0.28–1.4) 0.263
Cirrhosis (yes vs. no) 0.63 (0.24–1.7) 0.35
Hepatitis B etiology (yes vs. no) 1.1 (0.34–3.7) 0.865
Hepatitis C etiology (yes vs. no) 1.5 (0.68–3.1) 0.335
Alcohol etiology (yes vs. no) 0.61 (0.3–1.2) 0.164
TACE history (Yes vs. No) 1.2 (0.61–2.5) 0.578
PVI (yes vs. no) 0.55 (0.27–1.1) 0.099 0.66 (0.29–1.53) 0.337
Child–Pugh score (B vs. A) 1.5 (0.59–4.1) 0.377
BCLC stage (C vs. B) 0.57 (0.26–1.2) 0.155
Beyond up-to-7 (yes vs. no) 1.5 (0.44–4.8) 0.536
Tumor diameter (≥ 65 vs. < 65 mm) 2.2 (1.1–4.4) 0.021 1.31 (0.54–3.18) 0.545
AFP (≥ 400 vs < 400 ng/mL) 1.1 (0.54–2.4) 0.745
Diffuse disease (≥ 10 lesions) 1.3 (0.64–2.7) 0.457
Extrahepatic disease 1.6 (0.48–5.5) 0.431
Albumin 0.37 (0.17–0.77) 0.008 0.72 (0.29–1.8) 0.483
Bilirubin 0.51 (0.25–1) 0.058 0.83 (0.38–1.84) 0.649

Bold type indicates statistical significance